What Makes Cytokinetics Incorporated (NASDAQ: CYTK) One Of The Best Momentum Picks?

This post was originally published on this site

Cytokinetics Incorporated (NASDAQ:CYTK) shares, rose in value on Wednesday, 07/21/21, with the stock price up by 0.34% to the previous day’s close as strong demand from buyers drove the stock to $29.28.

Actively observing the price movement in the last trading, the stock closed the session at $29.18, falling within a range of $27.80 and $30.14. The value of beta (5-year monthly) was 1.38. Referring to stock’s 52-week performance, its high was $31.41, and the low was $14.71. On the whole, CYTK has fluctuated by 34.50% over the past month.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


With the market capitalization of Cytokinetics Incorporated currently standing at about $2.11 billion, investors are eagerly awaiting this quarter’s results, scheduled for Aug 04, 2021 – Aug 09, 2021. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.65, which is expected to increase to -$0.23 for fiscal year -$2.62 and then to about -$3.09 by fiscal year 2022. Data indicates that the EPS growth is expected to be -33.00% in 2022, while the next year’s EPS growth is forecast to be -17.90%.

Analysts have estimated the company’s revenue for the quarter at $5.45 million, with a low estimate of $2.08 million and a high estimate of $6.55 million. According to the average forecast, sales growth in current quarter could jump up 33.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $28.07 million, representing a decrease of -49.70% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CYTK’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 100% Buy.

10 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 8 recommend it as a Buy and 1 called the CYTK stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CYTK currently trading nearly 37.97% and 32.86% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 77.11, while the 7-day volatility ratio is showing 10.65% which for the 30-day chart, stands at 6.17%. Furthermore, Cytokinetics Incorporated (CYTK)’s beta value is 1.35, and its average true range (ATR) is 1.98. The company’s stock has been forecasted to trade at an average price of $42.60 over the course of the next 52 weeks, with a low of $26.00 and a high of $54.00. Based on these price targets, the low is 11.2% off current price, whereas the price has to move -84.43% to reach the yearly target high. Additionally, analysts’ median price of $43.00 is likely to be welcomed by investors because it represents a decrease of -46.86% from the current levels.

A comparison of Cytokinetics Incorporated (CYTK) with its peers suggests the former has fared considerably weaker in the market. CYTK showed an intraday change of 0.34% in last session, and over the past year, it grew by 22.66%%. In comparison, Eiger BioPharmaceuticals Inc. (EIGR) has moved higher at 1.96% on the day and was down -20.38% over the past 12 months. On the other hand, the price of Ligand Pharmaceuticals Incorporated (LGND) has risen 1.40% on the day. The stock, however, is off 1.69% from where it was a year ago. Additionally, there is a gain of 3.90% for Trevena Inc. (TRVN) in last trading while the stock has seen an overall depriciation of -21.57%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.82%. Meanwhile, the Dow Jones Industrial Improved by 0.83%.

Data on historical trading for Cytokinetics Incorporated (NASDAQ:CYTK) indicates that the trading volumes over the past 10 days have averaged 7.51 million and over the past 3 months, they’ve averaged 1.51 million. According to company’s latest data on outstanding shares, there are 71.19 million shares outstanding.

>> 7 Top Picks for the Post-Pandemic Economy <<

Nearly 1.30% of Cytokinetics Incorporated’s shares belong to company insiders. The data on short interest also indicates that stock shorts accounted for 9.08 million shares as on May 27, 2021, resulting in a short ratio of 11.06. According to the data, the short interest in Cytokinetics Incorporated (CYTK) stood at 12.66% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 9.39 million. The stock has risen by 40.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYTK stock heading into the next quarter.